[2-(2,6-dichloro-benzyl)-5-piperidin-1-yl-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine | 1160607-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(2,6-dichloro-benzyl)-5-piperidin-1-yl-thiazolo[5,4-d]pyrimidin-7-yl]-(4-trifluoromethyl-phenyl)-amine
• 英文别名: 2-[(2,6-dichlorophenyl)methyl]-5-piperidin-1-yl-N-[4-(trifluoromethyl)phenyl]-[1,3]thiazolo[5,4-d]pyrimidin-7-amine
• CAS: 1160607-85-1
• 化学式: C₂₄H₂₀Cl₂F₃N₅S
• 分子量: 538.424
• InChiKey: FJMHDUOZEUJPQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
  申请人：Branstetter Bryan James

  公开号：US20090156599A1

  公开（公告）日：2009-06-18

  Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  描述了某些调节TRPV1的咪唑基、噁唑基和噻唑吡啶化合物。这些化合物可用于制备药物组合物，并用于治疗由TRPV1活性介导的疾病状态、紊乱和症状，如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病。
• Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
  申请人：Andersen Sune Henrik

  公开号：US20070270408A1

  公开（公告）日：2007-11-22

  The use of substituted pyrazolo[1,5-a]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions are described. Also a novel class of substituted pyrazolo[1,5-a]pyrimidines their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  本文描述了使用取代的吡唑并[1,5-a]嘧啶类化合物来调节11β-羟类固醇脱氢酶1型（11βHSD1）活性的方法，并将这些化合物用作制药组合物。同时，本文还描述了一类新型的取代吡唑并[1,5-a]嘧啶类化合物及其在治疗中的应用，包括含有这些化合物的制药组合物以及这些化合物在制药中的应用。这些化合物是11βHSD1活性的调节剂，更具体地说是抑制剂，可以在需要降低细胞内活性糖皮质激素浓度的一系列医学疾病的治疗、预防和/或预防中发挥作用。
• IMIDAZOLO-, OXAZOLO-, AND THIAZOLOPYRIMIDINE MODULATORS OF TRPV1
  申请人：Branstetter Bryan James

  公开号：US20130005687A1

  公开（公告）日：2013-01-03

  Certain TRPV1-modulating imidazolo-, oxazolo-, and thiazolopyrimdine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  本文描述了某些调节TRPV1的咪唑啉、噁唑啉和噻唑嘧啶化合物。这些化合物可用于制备药物组合物和治疗TRPV1活性介导的疾病状态、紊乱和情况的方法，例如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病。
• Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines
  申请人：NOVO NORDISK A/S

  公开号：EP1782859A2

  公开（公告）日：2007-05-09

  The use of substituted pyrazolo[1,5-a]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions are described. Also a novel class of substituted pyrazolo[1,5-a]pyrimidines their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.

  描述了取代的吡唑并[1,5-a]嘧啶在调节 11β- 羟类固醇脱氢酶 1 型（11βHSD1）活性方面的用途，以及这些化合物作为药物组合物的用途。此外，还介绍了一类新型的取代吡唑并[1,5-a]嘧啶，它们在治疗中的用途、包含这些化合物的药物组合物以及它们在制造药物中的用途。本化合物是 11βHSD1 活性的调节剂，更具体地说是抑制剂，可用于治疗、预防和/或预防一系列需要降低细胞内活性糖皮质激素浓度的疾病。
• Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
  申请人：NOVO NORDISK A/S

  公开号：EP1854487A2

  公开（公告）日：2007-11-14

  Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.

  由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法，用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调，并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。